AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial

AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial

Submitted by admin on September 12, 2023 - 10:37am
Source: 
Clinical Trials Arena
News Tags: 
AstraZeneca
Fasenra
GSK
Nucala
eosinophilic granulomatosis with polyangiitis
clinical trials
Headline: 
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial
snippet: 

The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with eosinophilic granulomatosis with polyangiitis.

Do Not Allow Advertisers to Use My Personal information